These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 4875017)

  • 21. [Specific treatment of excessive iron deposition in the tissues].
    Plachecka-Gutowska M; Mikolajew M
    Pol Arch Med Wewn; 1965; 35(1):111-7. PubMed ID: 5900073
    [No Abstract]   [Full Text] [Related]  

  • 22. Simplified deferoxamine test in normal, diabetic, and iron-overload patients. Clinical observations.
    Rosen BJ; Tullis JL
    JAMA; 1966 Jan; 195(4):261-4. PubMed ID: 5951810
    [No Abstract]   [Full Text] [Related]  

  • 23. [Hemochromatosis].
    Phlippen R
    Munch Med Wochenschr; 1972 Feb; 114(5):147-9. PubMed ID: 5066916
    [No Abstract]   [Full Text] [Related]  

  • 24. Measurement of iron stores using deferoxamine.
    Balcerzak SP; Westerman MP; Heinle EW; Taylor FH
    Ann Intern Med; 1968 Mar; 68(3):518-25. PubMed ID: 5643675
    [No Abstract]   [Full Text] [Related]  

  • 25. [Iron-overload in patients on maintenance hemodialysis: diagnostic criteria, indications and treatment by desferrioxamine (author's transl)].
    Simon P; Bonn F; Guezennec M; Tanquerel T; Ksang
    Nephrologie; 1981; 2(4):165-70. PubMed ID: 7329501
    [TBL] [Abstract][Full Text] [Related]  

  • 26. THE TREATMENT OF HAEMOCHROMATOSIS WITH DESFERRIOXAMINE.
    WOEHLER F
    Acta Haematol; 1963 Aug; 30():65-87. PubMed ID: 14064792
    [No Abstract]   [Full Text] [Related]  

  • 27. Hemosiderosis and hemochromatosis in renal transplant recipients. Clinical and pathological features, diagnostic correlations, predisposing factors, and treatment.
    Rao KV; Anderson WR
    Am J Nephrol; 1985; 5(6):419-30. PubMed ID: 3909817
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Serum ferritin, free erythrocyte protoporphyrin, and urinary iron excretion in patients with iron disorders.
    Walsh JR; Fredrickson M
    Am J Med Sci; 1977; 273(3):293-300. PubMed ID: 868919
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Iron metabolism: theoretical and practical aspects (author's transl)].
    Ganzoni AM
    Ther Umsch; 1973 Nov; 30(11):754-9. PubMed ID: 4756549
    [No Abstract]   [Full Text] [Related]  

  • 30. [A NEW TEST FOR ASCERTAINMENT OF STATES OF SIDEROSIS: THE DESFERRIOXAMINE TEST. PRELIMINARY RESULTS].
    SCURO LA; BROCCIA G; DOBRILLA G; TAGLIAMONTE A
    Policlinico Prat; 1964 Jul; 71():1101-13. PubMed ID: 14174378
    [No Abstract]   [Full Text] [Related]  

  • 31. [Post-desferrioxamine urinary iron in iron-overload states].
    Santiago Corchado M; Ribas Ozonas B
    Rev Clin Esp; 1970 Jul; 118(2):151-8. PubMed ID: 5486372
    [No Abstract]   [Full Text] [Related]  

  • 32. Evaluation and interpretation of iron in the liver.
    Turlin B; Deugnier Y
    Semin Diagn Pathol; 1998 Nov; 15(4):237-45. PubMed ID: 9845425
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Detoxification in hemosiderosis.
    Simon P
    Blood Purif; 1985; 3(1-3):75-88. PubMed ID: 3913449
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Desferal therapy in iron storage disease.
    Thompson RB; Owen DM; Bell WN
    Am J Med Sci; 1967 Apr; 253(4):453-60. PubMed ID: 6021380
    [No Abstract]   [Full Text] [Related]  

  • 35. [Respective variations of sideremia and sideruria in cirrhotic patients following the desferrioxamine B test].
    Aron E; Weill JD; Jobard P; Galand A; Domenech J
    Arch Fr Mal App Dig; 1966 Sep; 55(9):824. PubMed ID: 5976364
    [No Abstract]   [Full Text] [Related]  

  • 36. [Further experiences with iron-chelating therapy (desferrioxamine and ascorbic acid) in siderochromatosis and Cooley's disease].
    Cartei G; Cazzavillan M; Chisesi T; Battista R; Barbui T; Dini E
    Minerva Med; 1978 Mar; 69(13):811-21. PubMed ID: 643223
    [No Abstract]   [Full Text] [Related]  

  • 37. Iron chelation by deferoxamine in sickle cell patients with severe transfusion-induced hemosiderosis: a randomized, double-blind study of the dose-response relationship.
    Silliman CC; Peterson VM; Mellman DL; Dixon DJ; Hambidge KM; Lane PA
    J Lab Clin Med; 1993 Jul; 122(1):48-54. PubMed ID: 8320490
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Iron metabolism and chelation therapy in hemosiderosis.
    Graziano JH
    Curr Top Hematol; 1978; 1():127-50. PubMed ID: 400529
    [No Abstract]   [Full Text] [Related]  

  • 39. [Changes in urinary iron in thalassemia major in relation to the administration of desferrioxamine].
    Esposito L; Ferrara M; Galdo Capotorti M
    Pediatria (Napoli); 1978 Mar; 86(1):69-76. PubMed ID: 683795
    [No Abstract]   [Full Text] [Related]  

  • 40. Iron overload disorders: natural history, pathogenesis, diagnosis, and therapy.
    McLaren GD; Muir WA; Kellermeyer RW
    Crit Rev Clin Lab Sci; 1983; 19(3):205-66. PubMed ID: 6373141
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.